Open AccessDouble‐blind trial of recombinant γ‐interferon versus placebo in the treatment of rheumatoid arthritis
Author(s) -
Grant W Can,
Seth H Pincus,
Ronald D Emkey,
Alex Denes,
Selwyn A Cohen,
Frederick Wolfe,
P Anthony Saway,
Adrian M Jaffer,
Arthur L Weaver,
Lewis Cogen,
John D Schindler
Publication year - 2008
Publication title -
arthritis & rheumatism
Language(s) - English
Resource type - Journals
eISSN - 1529-0131
pISSN - 0004-3591
DOI - 10.1002/art.23361
Subject(s) - rheumatoid arthritis , placebo , medicine , arthritis , rheumatism , physical therapy , double blind , recombinant dna , placebo group , alternative medicine , pathology , biochemistry , chemistry , gene
One hundred five patients were enrolled in a 12-week, randomized, prospective, double-blind, placebo-controlled trial of recombinant human gamma-interferon (rHu gamma-IFN) for the treatment of rheumatoid arthritis. Fifty-four patients received rHu gamma-IFN and 51 received placebo. Forty-two patients in each group completed the 12-week trial. Some clinical improvement occurred in both groups of patients. Although the improvement with rHu gamma-IFN was greater than that with placebo, the differences were generally not statistically significant.